Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
05/2003
05/21/2003CN1418870A 3,4-dibidro-1H-anphthalene derivatives used as high selectivity inhibitor of cyclooxygenase-2
05/21/2003CN1418694A Traditional Chinese medicine prepn. for treating diseases based on blood-deficiency
05/21/2003CN1418685A Medicine composition for treating and its prepn. method
05/21/2003CN1109036C New process for prepn. of pharmacologically active substance
05/21/2003CN1108817C Thrombolytic medicine
05/21/2003CN1108816C Gluconokinase microemulsion and preparing process thereof
05/21/2003CN1108806C Ningxueling capsule
05/20/2003US6566543 2-arachidonylglycerol (2-AG)-an inhibitor of tumor necrosis factor-α and neuroprotector of brain in closed head injury
05/20/2003US6566498 Proteins for use in the treatment of thrombosis and tumor metastisis
05/20/2003US6566493 Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
05/20/2003US6566387 For therapy of psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock
05/20/2003US6566379 Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors
05/20/2003US6566372 Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer
05/20/2003US6566357 Spirocyclic-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
05/20/2003US6566335 Administering a peptide derivative for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood
05/20/2003US6566140 Inhibition of coagulation in blood and blood products
05/20/2003US6566065 Diagnosing schizophrenia in humans; obtain sample, analyze the methylenetetrahydrofolate reductase nucleic acid expression in sample, genotype sample, presence of mutation indicates schizophrenia
05/20/2003US6565831 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/20/2003CA2215534C Stable protein: phospholipid compositions and methods
05/20/2003CA2099994C Phenyl amidines derivatives useful as platelet aggregation inhibitors
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040176A2 Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins
05/15/2003WO2003040121A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003WO2003040110A1 Triazole derivatives as cyclooxygenase (cox) inhibitors
05/15/2003WO2003040099A1 Preparation of benzosuberonylpiperidine compounds
05/15/2003WO2003040086A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003039590A1 Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
05/15/2003WO2003039589A1 Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides
05/15/2003WO2003039588A1 Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors
05/15/2003WO2003039587A1 Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
05/15/2003WO2003039586A1 Pharmaceutical composition comprising factor vii polypeptides and thrombomodulin polypeptides
05/15/2003WO2003039585A1 Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
05/15/2003WO2003039584A1 Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
05/15/2003WO2003039581A1 Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
05/15/2003WO2003039580A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003WO2003039579A1 Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
05/15/2003WO2003039564A1 Selective targeting of apoptotic cells
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039543A1 Derivatives of phenoxy-n-'4-(isothiazolidin-1,1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor xa in the treatment of thromboembolic diseases and tumors
05/15/2003WO2003039523A2 OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
05/15/2003WO2003039476A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039451A2 Thiazole pyridazinones as adenosine antagonists
05/15/2003WO2003039439A2 Deuterated pyrazolopyrimidinones and drugs containing said compounds
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039341A2 Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002029025A9 Factor vii glycoforms
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002004423A9 Thrombin inhibitors comprising an aminoisoquinoline group
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003US20030093819 Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092712 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092698 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
05/15/2003US20030092679 Novel non-convalent thrombin inhibitors
05/15/2003US20030092671 Synergistic mixture of low molecular weight heparin and dermatan sulfate; anticoagulants
05/15/2003US20030092633 Preventing desensitization of receptors
05/15/2003US20030092627 For treatment or prophylaxis of bleeding episodes; kits
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092133 Interleukins-21 and 22
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030091669 Mixture saponin, sugars and protein; solvent extraction, drying, sterilization; brain disorders, Alzheimer's disease
05/15/2003US20030091642 Composition in the form of a gel for receiving an active ingredient in a solution or suspension, especially for application on a mucous membrane and method of production thereof
05/15/2003US20030091630 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091571 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
05/15/2003US20030091559 Biocompatibility; liquid phase
05/15/2003US20030091558 Storage-stable fibrinogen solutions
05/15/2003US20030091549 Antiinflammatory agents; inflammatory bowel disease; gastrointestinal disorders
05/15/2003CA2470271A1 Deuterated pyrazolopyrimidinones and drugs containing said compounds
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2466232A1 Systems for delivery and release of angiotensin-(1-7)
05/15/2003CA2466030A1 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003CA2465713A1 Derivatives of phenoxy-n-'4-(1,1-dioxoisothiazolidin-2-yl)phenyl!-valeramide and other compounds as inhibitors of coagulation factor xa for the treatment of thromboembolic diseases and tumours
05/15/2003CA2465239A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003CA2465186A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003CA2464763A1 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
05/15/2003CA2464615A1 Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
05/15/2003CA2464614A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003CA2463745A1 Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins
05/14/2003EP1310571A2 A Method of detecting and/or identifying adeno-associated virus (AVV) sequences and isolating novel sequences identified thereby
05/14/2003EP1310558A2 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
05/14/2003EP1310493A1 N-adamantylalkyl benzamide derivates as p2x7-receptor antagonists
05/14/2003EP1309706A2 Modulation of stem cell differentiation
05/14/2003EP1309684A2 Polynucleotides and polypeptides encoded thereby
05/14/2003EP1309611A1 Anti-heparin peptides
05/14/2003EP1309609A2 Lactam compounds and their use as inhibitors of serine proteases and method
05/14/2003EP1309594A1 Benzimidazole derivatives, preparation and therapeutic use thereof
05/14/2003EP1309589A2 Urea compounds and methods of uses
05/14/2003EP1309575A1 Biphenyl derivatives and their use as ppar-gamma receptor activators
1 ... 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 ... 671